Guangshengtang hepatitis B treatment of the global innovative drug HBsAg inhibitor GST-HG131 was approved by the Clinical Trial Ethics Committee.

Guide: GST-HG131 is expected to become the world's first new hepatitis B HBsAg small molecule inhibitor innovation.
Fujian Guangshengtang Pharmaceutical Co., Ltd. recently obtained the review opinion of the first hospital ethics committee of Jilin University on the clinical trial and research of GBsAg inhibitor GBAg inhibitor GST-HG131 for the treatment of hepatitis B, indicating that the Phase Ia clinical trial program has been approved and approved for substantive implementation.
Guangshengtang hepatitis B treatment global innovation drug GST-HG131 has been researched and developed for five years, is the company's hepatitis B clinical cure "peak plan" combination of the important components.
GST-HG131 is the world's leading first-in-Class program and is expected to become the world's first globally listed hepatitis B HBsAg small molecule inhibitor innovation.
preclinical and in vivo pharmacodynamic studies show that GST-HG131 can induce HBsAgmRNA degradation, quickly reduce HBsAg levels by more than 1Log10, and have good safety.
.